Quality data characterising the suitability and tractability for future drug targets is critical to ensure the optimal likelihood of success in delivering tomorrow’s clinical breakthroughs. At o2h discovery we have experience supporting drug discovery endeavours from inception through to pre-clinical model studies. Our Biology team holds considerable experience drawn from both industrial and academic training, allowing us to bring immediate familiarity of subject matter to bear on most target classes and a broad range of indications.
Our active pipeline of projects frequently includes early-stage and exploratory services where we assist the validation of targets, deliver proof of concept for functional assays and establish feasibility of developability of early hits. We also hold extensive experience advancing projects through translational stages and can coordinate pre-clinical studies with trusted partners. Furthermore, we are equally well equipped to progress drug-discovery campaigns that begin on a target-agnostic footing.
o2h discovery actively curate a panel of disease-relevant cell lines and have expertise utilising a range of 2D and 3D culture formats. We can offer considerable support in characterising cellular phenotypes and mechanism-relevant biomarkers including expression profiles, alternative splicing, high-content phenotypic classification, subpopulation dynamics, genetic modification and diverse reporter technologies to drive functional analyses.
To know more about our integrated drug discovery service offerings or to request our brochure, please reach out to us at discovery@o2h.com.
